secwatch.observer — SEC 8-K summary
======================================

Issuer:     HOOKIPA Pharma Inc. (HOOK)
CIK:        0001760542
Form:       8-K
Filed at:   2023-05-31T23:59:59+00:00
Accession:  0001104659-23-066700
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HOOKIPA Phase 2 HB-200 data: 43% ORR with pembrolizumab vs 19% historical; pivotal trial planned for 2024
--------------------------------------------------------------------------------

- HB-200 + pembrolizumab showed 43% objective response rate (6/14 patients) in 1st-line HPV16+ head/neck cancer, doubling pembrolizumab alone.
- Median overall survival of 14.2 months in heavily pre-treated monotherapy cohort (n=11, median follow-up 12.8 months).
- Safety: 7% serious adverse events related to HB-200; 2% discontinuation rate across 132 patients.
- Company preparing to start pivotal trial of HB-200 + pembrolizumab in 1st-line setting in 2024.
- HB-200 induced rapid, sustained T-cell responses for at least 8 months associated with clinical benefit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1760542/000110465923066700/0001104659-23-066700-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1760542/000110465923066700/tm2317399d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-066700

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer